David I. Gwynne
Corporate Officer/Principal chez NeuroHealing Pharmaceuticals, Inc.
Profil
David I.
Gwynne is currently the Vice President-Business Development at NeuroHealing Pharmaceuticals, Inc. He previously held the position of Vice President-Business Development at Indevus Pharmaceuticals, Inc. He also worked as a Principal at CeNeS Pharmaceuticals, Inc., Cita NeuroPharmaceuticals, Inc., Allelix Biopharmaceuticals, Inc., and Cenes Ltd.
Dr. Gwynne earned a doctorate degree from McGill University.
Postes actifs de David I. Gwynne
| Sociétés | Poste | Début |
|---|---|---|
NeuroHealing Pharmaceuticals, Inc.
 NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | Corporate Officer/Principal | 01/01/1984 |
Anciens postes connus de David I. Gwynne
| Sociétés | Poste | Fin |
|---|---|---|
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
CeNeS Pharmaceuticals, Inc.
 CeNeS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CeNeS Pharmaceuticals, Inc. discovers and develops proprietary pharmaceuticals to prevent and treat disorders and injuries of the nervous system. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Cenes Ltd.
 Cenes Ltd. Medical SpecialtiesHealth Technology Part of PAION AG, Cenes Ltd. develops treatments for diseases of the central nervous system. The company is based in Histon, UK. | Corporate Officer/Principal | - |
| Allelix Biopharmaceuticals, Inc. | Corporate Officer/Principal | - |
Formation de David I. Gwynne
| McGill University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | Health Technology |
| Allelix Biopharmaceuticals, Inc. | Health Technology |
CeNeS Pharmaceuticals, Inc.
CeNeS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CeNeS Pharmaceuticals, Inc. discovers and develops proprietary pharmaceuticals to prevent and treat disorders and injuries of the nervous system. The company is headquartered in Cambridge, MA. | Health Technology |
Cenes Ltd.
Cenes Ltd. Medical SpecialtiesHealth Technology Part of PAION AG, Cenes Ltd. develops treatments for diseases of the central nervous system. The company is based in Histon, UK. | Health Technology |
Cita NeuroPharmaceuticals, Inc.
Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
